ALNY icon

Alnylam Pharmaceuticals
ALNY

Overview Fund Activity

226 hedge funds and large institutions have $6.95B invested in Alnylam Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 76 increasing their positions, 64 reducing their positions, and 22 closing their positions.

Holders
226
Holders Change
+28
Holders Change %
+14.14%
% of All Funds
5.64%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.2%
New
52
Increased
76
Reduced
64
Closed
22
Calls
$90.2M
Puts
$81.5M
Net Calls
+$8.72M
Net Calls Change
+$6.2M

Top Buyers

1
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$532M
2
Fidelity Investments
2
Fidelity Investments
Massachusetts
$1.09B
3
Vanguard Group
3
Vanguard Group
Pennsylvania
$512M
4
PA
4
Perceptive Advisors
New York
$146M
5
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$53.2M

Top Sellers

1
SPC
1
Slate Path Capital
New York
$90.5M
2
Franklin Resources
2
Franklin Resources
California
$0
3
UBS AM
3
UBS AM
Illinois
$116M
4
State Street
4
State Street
Massachusetts
$155M
5
Dodge & Cox
5
Dodge & Cox
California
$733M
Name Market Value Shares Shares
Change 		Shares
Change %
Fidelity Investments
1
Fidelity Investments
Massachusetts
$1.09B 13,723,153 +815,270 +6%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$947M 11,869,048 -172,131 -1%
Dodge & Cox
3
Dodge & Cox
California
$733M 9,185,820 -213,425 -2%
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$532M 6,668,603 +2,500,634 +60%
Vanguard Group
5
Vanguard Group
Pennsylvania
$512M 6,419,508 +759,295 +13%
BlackRock
6
BlackRock
New York
$414M 5,188,191 +441,957 +9%
Baillie Gifford & Co
7
Baillie Gifford & Co
United Kingdom
$274M 3,431,316 +96,805 +3%
State Street
8
State Street
Massachusetts
$155M 1,937,151 -229,081 -11%
PA
9
Perceptive Advisors
New York
$146M 1,832,761 +729,286 +66%
Goldman Sachs
10
Goldman Sachs
New York
$121M 1,511,712 +127,718 +9%
UBS AM
11
UBS AM
Illinois
$116M 1,448,515 -282,566 -16%
BRC
12
Blue Ridge Capital
New York
$110M 1,376,700 -213,300 -13%
BB
13
BB Biotech
Switzerland
$97.4M 1,221,338 -20,000 -2%
GGHC
14
Gilder Gagnon Howe & Co
New York
$94.5M 1,185,380 -20,669 -2%
SPC
15
Slate Path Capital
New York
$90.5M 1,135,000 -865,000 -43%
RI
16
RTW Investments
New York
$83M 1,040,607 -51,909 -5%
Morgan Stanley
17
Morgan Stanley
New York
$81.2M 1,017,531 +315,795 +45%
BM
18
Bridger Management
New York
$60.5M 759,127 +32,036 +4%
Norges Bank
19
Norges Bank
Norway
$59.4M 744,415 +100,000 +16%
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$58.5M 733,650 +238,256 +48%
1WCM
21
12 West Capital Management
New York
$55.8M 700,000 – –
Janus Henderson Group
22
Janus Henderson Group
United Kingdom
$53.2M 667,333 +667,333 New
Geode Capital Management
23
Geode Capital Management
Massachusetts
$52.8M 662,405 +85,608 +15%
O
24
OrbiMed
New York
$51M 639,200 +557,000 +678%
First Trust Advisors
25
First Trust Advisors
Illinois
$50M 626,331 -67,853 -10%
1
2 3 4 5